Author: da Silva Júnior, Afonso Henrique ; Volkmann, Ana Carolina ; Marquardt, André Luiz ; Francisco, Isadora Bertini Martins ; de Aguiar, Catia Rosana Lange ; de Oliveira, Carlos Rafael Silva

Abstract:

This study aimed to compare the dyeing capacity of annatto dye on linen textile substrates under the influence of different mordants, such as ferrous sulphate, alum, chitosan, and poly(diallyldimethylammonium chloride) (PDDACl). Annatto dye was extracted in an alcoholic medium, and the concentrations of the dye compounds bixin and norbixin were determined using ultraviolet‐visible spectrophotometry. Dyeing experiments were conducted with 10% and 20% weight of material (s.p.m.) concentrations, both on mordant‐treated substrates and on substrates pre‐bleached only. The colour evaluation indicated better colour yields for substrates pretreated with alum and PDDACl, with colour strength (K/S) values of 41.14 and 38.74, respectively, for dyeing with 20% s.p.m. However, these substrates exhibited the highest colour deviation (∆E) values in washing and lightfastness tests. The substrate pretreated with ferrous sulphate and the substrate pre‐bleached only showed K/S values of 25.99 and 18.68, respectively, with the ferrous sulphate‐treated substrate exhibiting the lowest ∆E values in washing and lightfastness tests among all evaluated substrates. Chitosan‐cationised samples showed the lowest colour yield, with a K/S of 12.51. Regarding washing and lightfastness, the pre‐bleached only substrate and the chitosan‐pretreated substrate displayed intermediate ∆𝐸 values. The dyeing kinetics of pre‐bleached substrates exhibited pseudo‐first‐order behaviour, while for ferrous sulphate‐pretreated samples, pseudo‐second‐order behaviour was observed. Langmuir's adsorption model was suitable for pre‐bleached substrate dyeing and ferrous sulphate‐pretreated sample dyeing in adsorption isotherms. However, for mordanted samples, higher adsorption intensity was observed.

01 Apr 2025·JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE

Bixa orellana (Bixaceae) seeds as a potential source of bioactive compounds for modulating postprandial hyperglycemia

Article

Author: Guiomar Melgar Lalanne ; Maira Rubi Segura Campos ; Rafael Rojas Herrera ; Juan Luis Monribot-Villanueva ; Abraham Vidal-Limon ; José A. Guerrero-Analco ; Jonatan Jafet Uuh Narvaez

Abstract:

BACKGROUND:

α‐Amylase (α‐AMY) and α‐glucosidase (α‐GLU) inhibitors are important for controlling postprandial hyperglycemia (PHG). Bixa orellana (annatto) reported inhibitory activity against these enzymes because of its bioactive compound content. However, an understanding of its inhibitory mechanisms and metabolic profile is necessary to establish its therapeutic potential. The present study aimed to elucidate the inhibitory mechanisms of B. orellana extract (BOE) on α‐AMY and α‐GLU, identify and quantify its bioactive compounds using metabolomics (untargeted and targeted) analyses, and evaluate their interactions through in silico approaches.

RESULTS:

BOE exhibited IC50 values of 37.75 and 47.06 mg mL−1 for α‐AMY and α‐GLU, respectively, indicating mixed and competitive inhibition types. Thirty‐six putative compounds were identified by untargeted metabolomics, mainly fatty acids (dethiobiotin, occidentalol, palmitic acid, norbixin, among others). The most significant biosynthetic pathways included secondary metabolites (unclassified), unsaturated fatty acids, phenylpropanoids and flavonoid metabolism. Eighteen compounds were identified and quantified by the targeted analysis, such as l‐phenylalanine, gallic acid, protocatechuic acid and naringenin. In silico studies highlighted xanthoangelol, norbixin, myricetin and 26‐hydroxybrassinolide as key compounds with the highest binding affinities to enzyme active sites.

CONCLUSION:

BOE effectively inhibited α‐AMY and α‐GLU, with gallic acid, naringenin, xanthoangelol, norbixin and 26‐hydroxybrassinolide identified as key bioactive contributors. These findings provide molecular evidence of the inhibitory mechanisms of BOE and support its potential for PHG management and diabetes control. © 2024 Society of Chemical Industry.

01 Mar 2025·ULTRASONICS SONOCHEMISTRY

Ultrasound-assisted metabolite detection in different extraction processes of Bletilla striata and bitter metabolite detection

Article

Author: Zhou, Wenhao ; Mao, Jian ; Zhang, Mengying ; Feng, Yushen ; Zhou, Juan ; Wu, Yigao ; Wu, Dajun ; Jiang, Lan ; Cao, Yunpeng ; Liu, Fugui

Bletilla striata, a medicinal orchidaceous plant, is recognized for its significant pharmacological value. However, the lack of comparative metabolomic data across different extraction methods for analyzing its bioactive components has significantly undervalued the application potential of B. striata in the traditional Chinese medicine market. Using six ultrasound-assisted extraction methods and UPLC-MS/MS, this study identified 1,945 metabolites in B. striata extracts. The dominant categories were lipids (51.35%), flavonoids (18.00%), and phenolic acids (12.51%). KEGG analysis revealed alterations in flavonoids and isoflavonoids biosynthesis pathways. Thirteen bitter metabolites, including cinnamic acid, were identified in B. striata tubers, underscoring their potential pharmacological applications, such as anti-inflammatory, antioxidant and antibacterial activities. Optimizing different extraction methods can better preserve the bioactive components of B. striata extracts, thereby enhancing its potential applications in the food and pharmaceutical industries.

News (Medical) associated with Macuneos

11 Feb 2022

·www.globenewswire.com

New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry Age-Related Macular Degeneration, also called geographic atrophy (GA), there is currently no FDA-approved therapy. There are, however, several treatments that are currently in clinical trials. Apl-2, Zimura, Oracea, and others are the drug molecules recently being investigated for the treatment of late-stage dry AMD. Strong Dry Age-related Macular Degeneration pipeline is anticipated to augment the market. DelveInsight’s 'Dry Age-related Macular Degeneration Pipeline Insight 2021' report provides comprehensive global coverage of available, marketed, and pipeline Dry AMD therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the Dry Age-related Macular Degeneration pipeline domain. Key Takeaways from the Dry Age-related Macular Degeneration Pipeline Report DelveInsight’s Dry Age-related Macular Degeneration Pipeline analysis depicts a robust space with 45+ active players working to develop 45+ pipeline therapies. active players working to develop pipeline therapies. Some of the key pharmaceutical players working to develop potential drug candidates to improve the Dry Age-related Macular Degeneration treatment landscape include Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix, and others. and others. Key Dry Age-related Macular Degeneration pipeline therapies in various stages of development include ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics, and others. and others. In July 2021, IVERIC bio announced the early completion of patient enrollment in GATHER2, the Company's second pivotal clinical trial of Zimura® (avacincaptad pegol) in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). announced the early completion of patient enrollment in GATHER2, the Company's second pivotal clinical trial of in development for the treatment of Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). In June 2021 , Ocular Therapeutix and Mosaic Biosciences entered into strategic discovery collaboration targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property. , and entered into strategic discovery targeting the treatment of dry age-related macular degeneration. Under the terms of the agreement, Ocular Therapeutix has agreed to fund the research performed under the collaboration and retains all program inventions and associated intellectual property. The US Food and Drug Administration (FDA) has granted Fast Track designation to Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration. to (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy secondary to dry age-related macular degeneration. In January 2021 Gemini Therapeutics announced that GEM103 , the company’s investigational treatment for dry AMD, had been granted Fast Track designation by the FDA. announced that , the company’s investigational treatment for dry AMD, had been granted Fast Track designation by the FDA. In September 2020, the US FDA had granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration. the US FDA had granted Fast Track designation to for the treatment of geographic atrophy secondary to dry age-related macular degeneration. In December 2020 , Janssen Pharmaceuticals announced the acquisition of rights to Hemera Biosciences, LLC's investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD). , announced the of rights to Hemera Biosciences, LLC's investigational gene therapy HMR59, administered as a one-time, outpatient, intravitreal injection to help preserve vision in patients with geographic atrophy, a late-stage and severe form of age-related macular degeneration (AMD). On January 13, 2022, ONL Therapeutics, announced that it has closed on its second tranche of the Company’s Series B financing. The total proceeds raised in the Series B was $46.9 million upon Achieving ONL1204 Development Milestones. The company is advancing ONL1204 into open-angle glaucoma and GA associated with dry AMD. Request a sample and discover more about the report offerings @ Dry Age-related Macular Degeneration Pipeline Outlook The Dry Age-related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-related Macular Degeneration products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-related Macular Degeneration pipeline landscape. Dry Age-related Macular Degeneration Overview Age-related Macular Degeneration (AMD) is a degenerative disease of the ocular-posterior segment's center (the macula lutea) that causes slow degeneration of central vision and severe disability in affected individuals. Clinically, AMD is classified using various methods. One such approach is to categorize the disease as early-stage to late-stage (advanced AMD). Advanced AMD is divided into two types: nonexudative or atrophic AMD (dry AMD) and exudative or neovascular AMD (wet AMD). Find out more about the disease and recent developments @ Dry Age-related Macular Degeneration Pipeline Assessment Dry Age-related Macular Degeneration Pipeline Drugs Learn more about the novel and emerging Systemic Lupus Erythematosus pipeline therapies @Dry Age-related Macular Degeneration Pipeline Analysis Dry Age-related Macular Degeneration Therapeutics Assessment The Dry Age-related Macular Degeneration Pipeline report proffers an integral view of the Dry Age-related Macular Degeneration emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration. Scope of the Dry Age-related Macular Degeneration Pipeline Report Coverage : Global : Global Therapeutic Assessment By Dry Age-related Macular Degeneration Product Type: Mono, Combination Mono, Combination Therapeutic Assessment By Dry Age-related Macular Degeneration Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration Therapeutics Assessment By Dry Age-related Macular Degeneration Therapeutics Route of Administration: Oral, Intravenous, Inhalation, Subcutaneous Oral, Intravenous, Inhalation, Subcutaneous Therapeutics Assessment By Dry Age-related Macular Degeneration Therapies Molecule Type : Gene therapy, Stem cell therapy, Small molecules : Gene therapy, Stem cell therapy, Small molecules Therapeutics Assessment By Dry Age-related Macular Degeneration Therapies Mechanism of Action: Complement C5 inhibitors, Complement factor I replacements; Gene transference, Integrin inhibitors, Complement factor H replacements, Pluripotent stem cell therapies, Cell replacements, RNA interference, Gene transference; Vascular endothelial growth factor A inhibitors, Fibroblast growth factor inhibitor, Mitochondrial permeability transition pore inhibitors, Cardiolipin modulators. Complement C5 inhibitors, Complement factor I replacements; Gene transference, Integrin inhibitors, Complement factor H replacements, Pluripotent stem cell therapies, Cell replacements, RNA interference, Gene transference; Vascular endothelial growth factor A inhibitors, Fibroblast growth factor inhibitor, Mitochondrial permeability transition pore inhibitors, Cardiolipin modulators. Key Dry Age-related Macular Degeneration Companies : Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix and others : Alkeus Pharmaceuticals, Dobecure, Iveric Bio, Mitotech, Stealth BioTherapeutics, Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, Luxa Biotechnology, CHABiotech CO., Ltd, Regenerative Patch Technologies, Lineage Cell Therapeutics, Janssen Research & Development, Belite Bio, Katairo, Cognition Therapeutics, Eye Co Pty Ltd, Applied Genetic Technologies Corporation (AGTC), Aviceda Therapeutics, Kodiak Sciences, Ascentage Pharma, OliX Pharmaceutical, Nanoscope Therapeutics, Inc., Biophytis, Eyestem, Eyevensys, SanBio, Beta Therapeutics, MacRegen, Amarna Therapeutics, MeiraGTx, Cognition Therapeutics, Ocugen, Catalyst Biosciences, Endogena Therapeutics, Oculogenex, Clover Therapeutics, Retrotope, Stuart Therapeutics, Surrozen, 4D Pharma, Ocular Therapeutix and others Key Dry Age-related Macular Degeneration Pipeline Therapies: ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, AAVCAGsCD59, Tinlarebant (LBS-008), Remofuscin, CT1812, Fludrocortisone acetate, Complement factor H, AVD-104, KSI-601, Alrizomadlin, OLX301A, MCO-030, BIO-201, Eyecyte-RPE, EYS809, SB 623, BT-2180, Mitia, AMA004, OCU410, IVT CB 2782-PEG, CTX010, CTX020, RT011, 4P-020,Research Programme: Dry Age-related Macular Degeneration (dAMD), Research programme: regenerative therapeutics and others Dive deep into rich insights for emerging therapies and assessment, visit @ Dry Age-related Macular Degeneration Emerging Therapies Table of Contents For further information on the Dry Age-related Macular Degeneration current pipeline therapeutics, reach out @ Dry Age-related Macular Degeneration Ongoing Clinical Trials Related Reports Age-Related Macular Degeneration Pipeline "Age Related Macular Degeneration Pipeline Insights, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Age-Related Macular Degeneration market. Wet Age-Related Macular Degeneration (Wet AMD) Pipeline "Wet Age-Related Macular Degeneration (Wet AMD) Pipeline Insights, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Wet Age-Related Macular Degeneration (Wet AMD) market. Age-Related Vision Dysfunction Pipeline “Age-Related Vision Dysfunction Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Age-Related Vision Dysfunction market. Juvenile Macular Degeneration (Stargardt Disease) Pipeline "Juvenile Macular Degeneration (Stargardt Disease) Pipeline Insights, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Juvenile Macular Degeneration (Stargardt Disease) market. Dim or Night Vision Disturbances (DLD) Pipeline "Dim or Night Vision Disturbances (DLD) Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Dim or Night Vision Disturbances (DLD) market. Wet Macular Degeneration Pipeline "Wet Macular Degeneration Pipeline Insights, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Wet Macular Degeneration market. Latest Healthcare Blogs Most Promising Applications of AI In the Healthcare Widespread Usage of HPV Vaccines Reduces Cervical Cancers and Precancers Major Drugs Decision for Cardiovascular Diseases to Watch Through 2022 About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. For more insights, visit Pharma, Healthcare, and Biotech News

29 Apr 2021

·www.globenewswire.com

Biophytis Receives €980,000 DeepTech Funding from BPI

PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France’s DeepTech program, for its MACA program of Macuneos (BIO201) in dry Age-Related Macular Degeneration (AMD). The DeepTech program aims to boost highly innovative and breakthrough projects emerging from fundamental research with attractive dedicated financing tools. The funding consists of a conditional advance of €600,000 and a grant of €380,000 which will complement existing financing for preclinical studies of Biophytis’ MACA clinical program in treatment of dry AMD, an age-related degeneration of the macula, the central part of the retina. AMD is one of the leading causes of irreversible vision loss and blindness in people over the age of 50. Stanislas Veillet, President and CEO of Biophytis, said: “We are pleased with this funding award, which recognizes the potential of Biophytis’ Macuneos (BIO201), which has demonstrated promising results in preclinical studies. There is still no available treatment for dry AMD and the loss of vision has a significant impact on patients’ quality of life. Macuneos (BIO201) has the potential to address a major unmet medical need and we look forward to further investigating it in clinical phases.” Biophytis plans to initiate a Phase 1 clinical trial (MACA-PK) in healthy volunteers in the second half of 2021, subject to regulatory review and approval as well as COVID-19-related delays and the impact of the pandemic on operational capabilities. Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. It is a plant-derived pharmaceutical-grade purified 9 cis-norbixin, or norbixin. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies. Biophytis believes that the results from preclinical studies support continued investigation to whether Macuneos (BIO201) may stimulate biological resilience and protect the retina against phototoxic damage that leads to vision loss. Dry AMD is a common eye disorder among people over the age of 50 that affects central vision, impairing functions such as reading, driving, and facial recognition, and has a major impact on quality of life and the ability to live independently. There are currently no approved drugs for dry AMD. Based on estimates from publicly available information, AMD affects approximately 8.5% of the global population (ages 45 to 85) and is expected to increase over time as the population ages. About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit DisclaimerThis press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Biophytis Contact for Investor RelationsEvelyne Nguyen, CFO evelyne.nguyen@biophytis.com Media contactLife Sci Advisors Sophie Baumont/Chris MaggosE: sophie@lifesciadvisors.comT: +33 6 27 74 74 49 Investor RelationsLifeSci Advisors, LLC Ligia Vela-ReidE: lvela-reid@lifesciadvisors.com

CollaborateSmall molecular drug

29 Apr 2021

·www.biospace.com

Biophytis Receives €980,000 DeepTech Funding from BPI France for the development of Macuneos (BIO201) in Dry AMD

DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021 PARIS and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it was granted a non-dilutive funding of €980,000 from the public investment bank BPI France’s DeepTech program, for its MACA program of Macuneos (BIO201) in dry Age-Related Macular Degeneration (AMD). The DeepTech program aims to boost highly innovative and breakthrough projects emerging from fundamental research with attractive dedicated financing tools. The funding consists of a conditional advance of €600,000 and a grant of €380,000 which will complement existing financing for preclinical studies of Biophytis’ MACA clinical program in treatment of dry AMD, an age-related degeneration of the macula, the central part of the retina. AMD is one of the leading causes of irreversible vision loss and blindness in people over the age of 50. Stanislas Veillet, President and CEO of Biophytis, said: “We are pleased with this funding award, which recognizes the potential of Biophytis’ Macuneos (BIO201), which has demonstrated promising results in preclinical studies. There is still no available treatment for dry AMD and the loss of vision has a significant impact on patients’ quality of life. Macuneos (BIO201) has the potential to address a major unmet medical need and we look forward to further investigating it in clinical phases.” Biophytis plans to initiate a Phase 1 clinical trial (MACA-PK) in healthy volunteers in the second half of 2021, subject to regulatory review and approval as well as COVID-19-related delays and the impact of the pandemic on operational capabilities. Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. It is a plant-derived pharmaceutical-grade purified 9 cis-norbixin, or norbixin. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathies. Biophytis believes that the results from preclinical studies support continued investigation to whether Macuneos (BIO201) may stimulate biological resilience and protect the retina against phototoxic damage that leads to vision loss. Dry AMD is a common eye disorder among people over the age of 50 that affects central vision, impairing functions such as reading, driving, and facial recognition, and has a major impact on quality of life and the ability to live independently. There are currently no approved drugs for dry AMD. Based on estimates from publicly available information, AMD affects approximately 8.5% of the global population (ages 45 to 85) and is expected to increase over time as the population ages. About BIOPHYTIS Biophytis SA is a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19. Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT). It is also being studied in a clinical two-part Phase 2-3 study (COVA) for the treatment of severe respiratory manifestations of COVID-19 in Europe, Latin America, and the US. A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825) and ADSs are listed on Nasdaq Capital Market (Ticker BPTS – ISIN: US09076G1040). For more information visit Disclaimer This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include statements regarding Biophytis’ anticipated timing for its Interim Analysis of Part 1 and release of full study results. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties including, without limitation, delays in patient recruitment or retention, interruptions in sourcing or supply chain, its ability to obtain the necessary regulatory authorizations, COVID-19-related delays, and the impact of the current pandemic on the Company’s clinical trials. The forward-looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. In France, please also refer to the "Risk Factors" section of the Company's Annual 2019 Report and the Company’s Half Year 2020 Report available on BIOPHYTIS website (). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Biophytis Contact for Investor Relations Evelyne Nguyen, CFO evelyne.nguyen@biophytis.com Media contact Life Sci Advisors Sophie Baumont/Chris Maggos E: sophie@lifesciadvisors.com T: +33 6 27 74 74 49 Investor Relations LifeSci Advisors, LLC Ligia Vela-Reid E: lvela-reid@lifesciadvisors.com

CollaborateSmall molecular drug

100 Deals associated with Macuneos

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15201

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
dry age-related macular degeneration	Preclinical	France	Biophytis SA	29 Aug 2023
Stargardt Disease	Preclinical	France	Biophytis SA	27 Oct 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis